###begin article-title 0
Regulation of class switch recombination and somatic mutation by AID phosphorylation
###end article-title 0
###begin p 1
###xml 38 65 38 65 <email xmlns:xlink="http://www.w3.org/1999/xlink">nussen@mail.rockefeller.edu</email>
CORRESPONDENCE Michel C. Nussenzweig: nussen@mail.rockefeller.edu
###end p 1
###begin p 2
This article is distributed under the terms of an Attribution-Noncommercial-Share Alike-No Mirror Sites license for the first six months after the publication date (see ). After six months it is available under a Creative Commons License (Attribution-Noncommercial-Share Alike 3.0 Unported license, as described at ).
###end p 2
###begin p 3
###xml 1064 1068 <span type="species:ncbi:10090">mice</span>
Activation-induced cytidine deaminase (AID) is a mutator enzyme that initiates somatic mutation and class switch recombination in B lymphocytes by introducing uracil:guanine mismatches into DNA. Repair pathways process these mismatches to produce point mutations in the Ig variable region or double-stranded DNA breaks in the switch region DNA. However, AID can also produce off-target DNA damage, including mutations in oncogenes. Therefore, stringent regulation of AID is required for maintaining genomic stability during maturation of the antibody response. It has been proposed that AID phosphorylation at serine 38 (S38) regulates its activity, but this has not been tested in vivo. Using a combination of mass spectrometry and immunochemical approaches, we found that in addition to S38, AID is also phosphorylated at position threonine 140 (T140). Mutation of either S38 or T140 to alanine does not impact catalytic activity, but interferes with class switching and somatic hypermutation in vivo. This effect is particularly pronounced in haploinsufficient mice where AID levels are limited. Although S38 is equally important for both processes, T140 phosphorylation preferentially affects somatic mutation, suggesting that posttranslational modification might contribute to the choice between hypermutation and class switching.
###end p 3
###begin p 4
Abbreviations used: AID, activation-induced cytidine deaminase; CSR, class switch recombination; GC, germinal center; PKA, protein kinase A; PKC, protein kinase C; s38, serine 38; SHM, somatic hypermutation; ss, single-stranded; T140, threonine 140.
###end p 4
###begin p 5
###xml 125 127 125 127 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ig</italic>
###xml 342 343 342 343 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib1">1</xref>
###xml 345 346 345 346 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib2">2</xref>
###xml 563 564 563 564 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib3">3</xref>
###xml 566 567 566 567 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib4">4</xref>
###xml 655 657 655 657 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ig</italic>
###xml 673 674 673 674 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib5">5</xref>
###xml 891 892 891 892 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib3">3</xref>
###xml 894 895 894 895 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib4">4</xref>
###xml 1058 1059 1058 1059 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib6">6</xref>
###xml 1060 1062 1060 1062 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib11">11</xref>
###xml 1381 1383 1381 1383 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib12">12</xref>
###xml 1384 1386 1384 1386 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib14">14</xref>
###xml 1468 1470 1468 1470 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ig</italic>
###xml 1476 1478 1476 1478 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib15">15</xref>
###xml 1479 1481 1479 1481 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib19">19</xref>
The immune system produces a diverse array of antibodies by a series of DNA transactions that require programmed DNA damage. Ig transcription units are assembled by random joining of variable (V), diversity (D), and joining (J) gene segments by a site-specific recombination reaction mediated by RAG1 and RAG2 proteins in developing B cells (1, 2). Later, during immune responses, antigen-specific clones of B cells are selectively expanded in structures called germinal centers (GCs), where they undergo Ig somatic mutation and class switch recombination (CSR) (3, 4). Somatic hypermutation (SHM) introduces nontemplate nucleotide substitutions into the Ig variable gene (5), which can alter the binding affinity of the antibody molecule. If the affinity is enhanced, the resulting B cell clone is selectively expanded, ultimately resulting in affinity maturation of the antibody response (3, 4). CSR is a region-specific deletional recombination reaction that replaces one antibody-constant region for another, thereby altering antibody effector function (6-11). Class switching does not involve the variable regions, and therefore switched antibodies retain their antigenic specificity. Although somatic mutation and class switching are fundamentally different DNA transactions, they are initiated in the nucleus by the same enzyme, activation-induced cytidine deaminase (AID) (12-14), which introduces uracil:guanine mismatches in transcribed single-stranded (ss) Ig DNA (15-19).
###end p 5
###begin p 6
###xml 30 33 30 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Igs</italic>
###xml 118 122 118 122 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bcl6</italic>
###xml 126 131 126 131 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-myc</italic>
###xml 133 135 133 135 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib20">20</xref>
###xml 136 138 136 138 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib23">23</xref>
###xml 191 194 191 194 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Igs</italic>
###xml 251 253 251 253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib24">24</xref>
###xml 254 256 254 256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib26">26</xref>
###xml 368 370 368 370 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib13">13</xref>
###xml 429 431 429 431 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib27">27</xref>
###xml 433 435 433 435 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib28">28</xref>
In addition to its effects on Igs, AID produces off-target DNA damage, including point mutations in oncogenes such as bcl6 or c-myc (20-23), and it also induces double-stranded DNA breaks in Igs that serve as substrates for chromosome translocations (24-26). DNA damage by AID is minimized in part because AID expression is restricted to activated B cells within GCs (13) by a requirement for PAX5 and E47 transcription factors (27, 28).
###end p 6
###begin p 7
###xml 51 53 51 53 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib29">29</xref>
###xml 54 56 54 56 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib31">31</xref>
###xml 153 155 153 155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib30">30</xref>
###xml 157 159 157 159 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib32">32</xref>
###xml 295 297 295 297 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib33">33</xref>
###xml 298 300 298 300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib36">36</xref>
###xml 516 518 516 518 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib29">29</xref>
###xml 520 522 520 522 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib37">37</xref>
###xml 524 526 524 526 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib38">38</xref>
AID levels are limiting for CSR and hypermutation (29-31), and they are known to be regulated by microRNA-155, which controls the half-life of AID mRNA (30, 32). In addition, the concentration of AID in the nucleus is limited by a combination of active export and selective nuclear degradation (33-36). Finally, biochemical and tissue culture experiments indicate that a fraction of AID is posttranslationally modified by phosphorylation of serine 38 (S38) and that this modification may also regulate AID activity (29, 37, 38).
###end p 7
###begin p 8
###xml 159 161 159 161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib37">37</xref>
###xml 262 264 262 264 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib37">37</xref>
###xml 266 268 266 268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib38">38</xref>
###xml 499 501 499 501 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib37">37</xref>
###xml 590 592 590 592 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib29">29</xref>
S38 is thought to be a target of c-AMP-dependent protein kinase A (PKA) because S38 is part of a PKA consensus site and can be phosphorylated in vitro by PKA (37). Furthermore, coimmunoprecipitation experiments showed that AID is physically associated with PKA (37, 38). In biochemical assays phosphorylation at S38 is essential for AID to associate with replication protein A (RPA), a single stranded DNA binding protein, and the interaction is required for AID to access actively transcribed DNA (37). Consistent with this observation, AID phosphorylated at S38 is enriched in chromatin (29).
###end p 8
###begin p 9
###xml 98 102 98 102 <sup xmlns:xlink="http://www.w3.org/1999/xlink">S38A</sup>
###xml 220 222 220 222 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib29">29</xref>
###xml 224 226 224 226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib37">37</xref>
###xml 228 230 228 230 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib39">39</xref>
###xml 250 254 250 254 <sup xmlns:xlink="http://www.w3.org/1999/xlink">S38A</sup>
###xml 368 370 368 370 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib29">29</xref>
###xml 372 374 372 374 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib37">37</xref>
###xml 376 378 376 378 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib38">38</xref>
###xml 380 382 380 382 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib40">40</xref>
###xml 456 458 456 458 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib41">41</xref>
###xml 646 648 646 648 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib41">41</xref>
###xml 649 651 649 651 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib43">43</xref>
###xml 415 422 <span type="species:ncbi:9031">chicken</span>
###xml 550 559 <span type="species:ncbi:7955">zebrafish</span>
Although the role of S38 phosphorylation has not been tested in vivo, mutating S38 to alanine (AIDS38A) results in catalytically intact AID, which may have an altered substrate preference in biochemical assays in vitro (29, 37, 39). Expression of AIDS38A has also been reported to variably decrease CSR assayed in AID-deficient B cells in vitro (10-80% of wild type) (29, 37, 38, 40) and SHM and gene conversion in chicken DT40 B cells (15% of wild type) (41). Further confounding the question of the function of S38 phosphorylation is the fact that zebrafish AID lacks a serine at this position, yet retains activity in CSR and gene conversion (41-43).
###end p 9
###begin p 10
In this study, we report on a novel site of AID phosphorylation at threonine 140 (T140) and examine the impact of S38 and T140 phosphorylation on CSR and SHM in vivo.
###end p 10
###begin title 11
RESULTS
###end title 11
###begin p 12
###xml 273 275 273 275 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib29">29</xref>
###xml 277 279 277 279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib37">37</xref>
###xml 336 344 336 344 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 A</xref>
To examine posttranslational modification of AID, we purified the protein from B cells cultured with LPS and IL-4 and subjected the material to mass spectrometry. Analysis of purified AID confirmed phosphorylation at peptides containing S38 (p38), and tyrosine 184 (p184) (29, 37) and revealed additional phosphorylation at T140 (p140; Fig. 1 A).
###end p 12
###begin p 13
###xml 0 39 0 39 <bold xmlns:xlink="http://www.w3.org/1999/xlink">AID is phosphorylated at position T140.</bold>
###xml 244 251 244 251 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli</italic>
###xml 331 334 331 334 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 244 251 <span type="species:ncbi:562">E. coli</span>
AID is phosphorylated at position T140. (A) Amino acid sequence of AID showing the location of S38 and T140 within consensus PKA and PKC sites, respectively (gray boxes). (B) Anti-p140 or -AID immunoblot of recombinant AID (rAID) purified from E. coli or FLAG-tagged AID or AID-T140A immunoprecipitated from retroviral infected AID-/- B cells (* denotes 27-kD FLAG-tagged AID). (C) Anti-p140 and -AID immunoblot of FLAG-tagged AID purified from B cells stimulated with LPS, LPS and IL-4, CpG, or anti-CD40 and IL-4. (D) Anti-p140 and -AID immunoblot of FLAG-tagged AID purified from B cells or NTZ-3T3 cells. (E) Anti-p140 and -AID immunoblot of rAID untreated (-) or treated with PKC or PKA in vitro. (F) Anti-p140, -p38, and -AID immunoblot of rAID untreated (-) or in vitro phosphorylated with the indicated PKC isoforms.
###end p 13
###begin p 14
###xml 237 245 237 245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 B</xref>
###xml 377 385 377 385 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 C</xref>
###xml 513 521 513 521 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 D</xref>
###xml 709 717 709 717 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 E</xref>
###xml 924 932 924 932 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 F</xref>
To confirm that AID is phosphorylated at T140 in vivo, we produced AID-p140 phosphospecific antibodies (anti-p140). Anti-p140 was reactive with AID purified from B cells stimulated with LPS and IL-4, but was not reactive with AID-T140A (Fig. 1 B). The level of anti-p140 reactivity in cultured B cells differed depending on the stimulus with the highest levels found with CpG (Fig. 1 C). However, phosphorylation at AID-T140 was not B cell specific and could also be detected in NIH-3T3 NTZ cells expressing AID (Fig. 1 D). Finally, anti-p140 did not react with recombinant AID produced in bacteria, but was reactive with AID phosphorylated in vitro with protein kinase C (PKC) catalytic subunit and not PKA (Fig. 1 E). The PKC family is composed of at least 10 serine/threonine kinases, and anti-p140 and -p38 was reactive to varying degrees with recombinant AID after in vitro phosphorylation with the different isoforms (Fig. 1 F). We conclude that AID is phosphorylated at position T140 and that this site of posttranslational modification resembles S38 in that it is not B cell specific.
###end p 14
###begin p 15
###xml 204 220 204 220 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Escherichia coli</italic>
###xml 222 224 222 224 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib19">19</xref>
###xml 263 266 263 266 <sup xmlns:xlink="http://www.w3.org/1999/xlink">P94</sup>
###xml 273 276 273 276 <sup xmlns:xlink="http://www.w3.org/1999/xlink">L94</sup>
###xml 370 372 370 372 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib19">19</xref>
###xml 483 491 483 491 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 A</xref>
###xml 494 496 494 496 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib29">29</xref>
###xml 571 578 571 578 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli</italic>
###xml 204 220 <span type="species:ncbi:562">Escherichia coli</span>
###xml 571 578 <span type="species:ncbi:562">E. coli</span>
To determine whether T140 is essential for catalytic activity, we compared wild-type and AID-T140A for their ability to revert an inactivating point mutation in a kanamycin resistance encoding plasmid in Escherichia coli (19). Reversion of the point mutation (CCAP94 to CTAL94) by cytidine deamination confers kanamycin resistance, which is assayed by colony formation (19). AID-T140A, AID-S38A, and the double mutant (AID-ST/AA) were indistinguishable from wild type in this assay (Fig. 2 A) (29). Thus, these mutations do not alter AID catalytic activity as assayed in E. coli.
###end p 15
###begin p 16
###xml 22 27 22 27 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T140A</sup>
###xml 36 40 36 40 <sup xmlns:xlink="http://www.w3.org/1999/xlink">S38A</sup>
###xml 0 93 0 93 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Comparison of AID, AID<sup>T140A</sup>, and AID<sup>S38A</sup> hypermutation and CSR activity in B and non&#8211;B cells.</bold>
###xml 163 164 163 164 <sup xmlns:xlink="http://www.w3.org/1999/xlink">R</sup>
###xml 202 206 202 206 <sup xmlns:xlink="http://www.w3.org/1999/xlink">S38A</sup>
###xml 211 216 211 216 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T140A</sup>
###xml 221 226 221 226 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ST-AA</sup>
###xml 319 323 319 323 <sup xmlns:xlink="http://www.w3.org/1999/xlink">S38A</sup>
###xml 331 336 331 336 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T140A</sup>
###xml 471 475 471 475 <sup xmlns:xlink="http://www.w3.org/1999/xlink">S38A</sup>
###xml 484 489 484 489 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T140A</sup>
###xml 797 801 797 801 <sup xmlns:xlink="http://www.w3.org/1999/xlink">S38A</sup>
###xml 806 811 806 811 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T140A</sup>
###xml 1135 1136 1135 1136 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 1205 1209 1205 1209 <sup xmlns:xlink="http://www.w3.org/1999/xlink">S38A</sup>
###xml 1218 1223 1218 1223 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T140A</sup>
###xml 1420 1424 1420 1424 <sup xmlns:xlink="http://www.w3.org/1999/xlink">S38A</sup>
###xml 1460 1465 1460 1465 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T140A</sup>
###xml 1544 1547 1544 1547 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1586 1590 1586 1590 <sup xmlns:xlink="http://www.w3.org/1999/xlink">S38A</sup>
###xml 1599 1604 1599 1604 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T140A</sup>
###xml 1613 1618 1613 1618 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ST-AA</sup>
###xml 1661 1664 1661 1664 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1711 1715 1711 1715 <sup xmlns:xlink="http://www.w3.org/1999/xlink">S38A</sup>
###xml 1724 1729 1724 1729 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T140A</sup>
###xml 1738 1743 1738 1743 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ST-AA</sup>
###xml 1861 1864 1861 1864 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1902 1906 1902 1906 <sup xmlns:xlink="http://www.w3.org/1999/xlink">S38A</sup>
###xml 1912 1917 1912 1917 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T140A</sup>
###xml 1923 1928 1923 1928 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ST-AA</sup>
###xml 2025 2026 2025 2026 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 2211 2215 2211 2215 <sup xmlns:xlink="http://www.w3.org/1999/xlink">S38A</sup>
###xml 2220 2225 2220 2225 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T140A</sup>
###xml 2230 2235 2230 2235 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ST-AA</sup>
###xml 2394 2397 2394 2397 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 2443 2447 2443 2447 <sup xmlns:xlink="http://www.w3.org/1999/xlink">S38A</sup>
###xml 2453 2458 2453 2458 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T140A</sup>
###xml 2464 2469 2464 2469 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ST-AA</sup>
###xml 2566 2567 2566 2567 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 2963 2964 2963 2964 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 2971 2972 2971 2972 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 2987 2988 2987 2988 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
Comparison of AID, AIDT140A, and AIDS38A hypermutation and CSR activity in B and non-B cells. (A) The graph shows a log plot of numbers of kanamycin-resistant (KanR) colonies after induction of AID, AIDS38A, AIDT140A, AIDST-AA, or empty vector expression. (B) Anti-p140, -p38, or -AID immunoblot of FLAG-tagged AID, AIDS38A, or AIDT140A purified from B cells stimulated with LPS and IL-4. (C) Accumulation of GFP-expressing 3T3-NTZ cells after transduction with AID-, AIDS38A-, or AIDT140A-expressing PMX-MK retroviruses. The x axis indicates the number of days after transduction, and the y axis indicates the percentage of GFP-positive cells measured by flow cytometry. (D) Number of mutations in the GFP gene cloned from 3T3-NTZ cells 11 d after transduction with retroviruses encoding AID, AIDS38A, AIDT140A, or control. Segment sizes in the pie charts are proportional to the number of sequences carrying the number of mutations indicated in the periphery of the charts. The total number of independent sequences analyzed is indicated in the center of each chart. Statistical significance was determined by a two-tailed Student's t test assuming unequal variance and comparing AID expressing with AIDS38A- and AIDT140A-expressing cells. P values are indicated. The numbers of point mutations were as follows: 4 mutations/21,643 bp mutations for vector; 59 mutations/13,174 bp for AID; 15 mutations/19,761 bp for AIDS38A; and 45 mutations/21,643 bp for AIDT140A. (E) Schematic of retroviral constructs used (top); anti-AID immunoblot of AID-/- B cells infected with PMX-AID, or -AIDS38A, or -AIDT140A, or -AIDST-AA (middle); or wild-type B cells (WT) or AID-/- B cells infected with PMX-AID, MK-AID, or -AIDS38A, or -AIDT140A, or -AIDST-AA (bottom). Anti-tubulin was used as a loading control. (F) Graph of flow cytometric analysis of IgG1 expression in AID-/- B cells transduced with PMX-AID, -AIDS38A, -AIDT140A, -AIDST-AA, or control vector and cultured in LPS plus IL-4 for 3 d after infection. The percentage of IgG1+ cells is indicated for five independent experiments, and the mean is indicated by a solid line. (G) Relative efficiency of isotype switching to IgG1. A comparison of PMX-AID versus AIDS38A, AIDT140A, AIDST-AA, or vector control. Bars represent the mean and SD from the five independent experiments in F. (H) Graph of flow cytometric analysis of IgG1 expression in AID-/- B cells transduced with PMX-AID, MK-AID, -AIDS38A, -AIDT140A, -AIDST-AA, or control vector and cultured in LPS plus IL-4 for 3 d after infection. The percentage of IgG1+ cells is indicated for three independent experiments, and the mean is indicated by a solid line. (I) Relative efficiency of isotype switching to IgG1. Bars represent the mean and SD from H. (J) Flow cytometric analysis of IgG1 expression in wild-type B cells alone or transduced with MK-AID, PMX-AID, or control vector and cultured in LPS plus IL-4 for 3 d after infection. The percentage of GFP- or GFP+ that were IgG1+ is indicated on the top left or right of each graph, respectively. Graphs are representative of three independent experiments.
###end p 16
###begin p 17
###xml 142 145 142 145 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 443 451 443 451 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 B</xref>
To determine whether there is interdependence between S38 and T140 phosphorylation, we expressed AID, AID-S38A, or AID-T140A in stimulated AID-/- B cells and performed Western blotting experiments with anti-p140 and -p38 antibodies. We found that AID-S38A was normally phosphorylated at position T140 and, conversely, that AID-T140A was normally phosphorylated at S38. We conclude that the two sites of phosphorylation are not interdependent (Fig. 2 B).
###end p 17
###begin p 18
###xml 42 50 42 50 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 D</xref>
###xml 263 265 263 265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib44">44</xref>
###xml 380 395 380 395 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2, C and D</xref>
###xml 398 400 398 400 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib29">29</xref>
AID is phosphorylated in 3T3 fibroblasts (Fig. 1 D) and mutates indicator substrates when it is expressed in these cells. Mutator activity can be measured by reversion of a green fluorescent protein indicator containing a premature stop codon (NIH-3T3 NTZ cells [44]). When assayed by FACS or sequencing, AID-S38A and -T140A showed <15 and <50% of wild-type levels, respectively (Fig. 2, C and D) (29). We conclude that T140 is required for normal levels of mutation in NIH-3T3 NTZ cells in vitro.
###end p 18
###begin p 19
###xml 154 156 154 156 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib45">45</xref>
###xml 310 318 310 318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 E</xref>
###xml 363 365 363 365 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib25">25</xref>
###xml 513 521 513 521 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 E</xref>
###xml 676 691 676 691 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2, F and H</xref>
###xml 756 771 756 771 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2, F and H</xref>
###xml 873 888 873 888 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2, F and G</xref>
###xml 989 1004 989 1004 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2, H and I</xref>
###xml 1157 1172 1157 1172 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2, G and I</xref>
###xml 1175 1177 1175 1177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib29">29</xref>
###xml 1179 1181 1179 1181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib37">37</xref>
###xml 1183 1185 1183 1185 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib38">38</xref>
###xml 1187 1189 1187 1189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib40">40</xref>
###xml 1442 1457 1442 1457 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2, F and G</xref>
AID can be assayed for its ability to induce CSR in B cells in vitro by retroviral complementation of AID-deficient B cells stimulated with LPS and IL-4 (45). Because AID expression levels may impact on the results of the assay, we used two retroviral vectors that directed different levels of AID expression (Fig. 2 E). B cell retroviral infection with PMX-AID (25) or MK-AID, which contains a mutant Kozak sequence, results in AID levels that are 10- or 2.5-fold higher than physiological levels, respectively (Fig. 2 E). Consistent with the high levels of AID expression, B cells infected with PMX-AID switched to IgG1 at higher efficiency than cells infected with MK-AID (Fig. 2, F and H). AID mutants showed varying degrees of activity in this assay (Fig. 2, F and H). High levels of AID-T140A expression reconstituted nearly 95% of control levels of class switching (Fig. 2, F and G). In contrast, lower levels of AID-T140A expression resulted in 50% of control levels of switching (Fig. 2, H and I). As previously reported, AID-S38A mutants varied in activity depending on expression levels ranging from nearly undetectable to 60% of control levels (Fig. 2, G and I) (29, 37, 38, 40). High-level expression of the double mutant, AID-ST/AA, resulted in a modest drop in class switching compared with AID-S38A, 35 versus 55% of control levels of switching, respectively, which is consistent with an additive effect of the two mutations (Fig. 2, F and G). We conclude that phosphorylation of S38 and T140 are important for class switching in LPS- and IL-4-stimulated B cells. Furthermore, higher levels of AID expression drive higher levels of switching to IgG1 and diminish the requirement for S38 or T140 phosphorylation. Therefore, the precise contribution of these posttranslational modifications to AID function is difficult to evaluate in this assay.
###end p 19
###begin p 20
###xml 397 405 397 405 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 J</xref>
To determine if AID protein levels are a rate-limiting factor in CSR, we augmented AID levels in wild-type LPS- and IL-4-stimulated B cells with retrovirally expressed AID and measured isotype switching to IgG1. Compared with wild type alone or wild type transduced with empty PMX retrovirus, cells supplemented with AID from the PMX-AID retrovirus displayed a >40% increase in isotype switching (Fig. 2 J). We conclude that AID levels are rate limiting and that superphysiological levels can drive higher rates of isotype switching.
###end p 20
###begin p 21
###xml 143 146 143 146 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AID</italic>
###xml 151 155 151 155 <sup xmlns:xlink="http://www.w3.org/1999/xlink">S38A</sup>
###xml 164 169 164 169 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T140A</sup>
###xml 213 217 213 217 <sup xmlns:xlink="http://www.w3.org/1999/xlink">S38A</sup>
###xml 225 230 225 230 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T140A</sup>
###xml 508 512 508 512 <sup xmlns:xlink="http://www.w3.org/1999/xlink">S38A</sup>
###xml 521 526 521 526 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T140A</sup>
###xml 593 601 593 601 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 A</xref>
###xml 624 627 624 627 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/&#8722;</sup>
###xml 632 638 632 638 <sup xmlns:xlink="http://www.w3.org/1999/xlink">S38A/&#8722;</sup>
###xml 647 654 647 654 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T140A/&#8722;</sup>
###xml 716 724 716 724 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 A</xref>
###xml 730 734 730 734 <sup xmlns:xlink="http://www.w3.org/1999/xlink">S38A</sup>
###xml 742 747 742 747 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T140A</sup>
###xml 853 868 853 868 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3, B and C</xref>
###xml 874 878 874 878 <sup xmlns:xlink="http://www.w3.org/1999/xlink">S38A</sup>
###xml 964 968 964 968 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T140</sup>
###xml 1029 1044 1029 1044 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3, B and C</xref>
###xml 1128 1131 1128 1131 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/&#8722;</sup>
###xml 1195 1201 1195 1201 <sup xmlns:xlink="http://www.w3.org/1999/xlink">S38A/&#8722;</sup>
###xml 1210 1217 1210 1217 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T140A/&#8722;</sup>
###xml 1281 1296 1281 1296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3, B and C</xref>
###xml 1432 1447 1432 1447 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3, B and C</xref>
###xml 1543 1547 1542 1546 <sup xmlns:xlink="http://www.w3.org/1999/xlink">S38A</sup>
###xml 1555 1560 1554 1559 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T140A</sup>
###xml 1627 1635 1626 1634 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 D</xref>
###xml 1737 1745 1736 1744 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 C</xref>
###xml 1853 1857 1852 1856 <sup xmlns:xlink="http://www.w3.org/1999/xlink">S38A</sup>
###xml 1942 1947 1941 1946 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T140A</sup>
###xml 2011 2026 2010 2025 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3, E and F</xref>
###xml 100 104 <span type="species:ncbi:10090">mice</span>
###xml 1110 1114 <span type="species:ncbi:10090">mice</span>
To examine the physiological function of AID phosphorylation at positions S38 and T140, we produced mice that carry S38A or T140A mutations in AID, AIDS38A, and AIDT140A, respectively (Fig. S1, available at ). AIDS38A and AIDT140A mutant B cells developed normally (not depicted) and were assayed for CSR to IgG1 after stimulation with LPS and IL-4 in culture. Cell division was monitored by labeling cells with CFSE and tracking dye dilution by flow cytometry. AID protein levels expressed by wild-type, AIDS38A, and AIDT140A B cells were indistinguishable when measured by Western blotting (Fig. 3 A), and heterozygous AID+/-, AIDS38A/-, and AIDT140A/- expressed half as much AID as their homozygous counterparts (Fig. 3 A). AIDS38A and AIDT140A B cells divided normally in response to LPS and IL-4, but were impaired in switch recombination to IgG1 (Fig. 3, B and C). AIDS38A mutant B cells showed 32% the level of CSR to IgG1 of wild-type controls, whereas AIDT140 produced a milder defect resulting in 87% of wild-type CSR (Fig. 3, B and C). In both cases, the defect was exacerbated in haploinsufficient mice. Although AID+/- B cells displayed IgG1 switching, 80% of wild-type B cells, AIDS38A/-, and AIDT140A/- showed 4 and 45% the level of wild-type B cells, respectively (Fig. 3, B and C). This relative decrease was consistent within each experiment, despite overall switching rates varying from experiment to experiment (Fig. 3, B and C). We also measured mutation within the region 5' of the Smu switch repeats. Similar to CSR, AIDS38A and AIDT140A had mutation rates of 25 and 85%, respectively, compared with WT (Fig. 3 D). Because different stimulation conditions may result in differential levels of AID phosphorylation (Fig. 1 C), we measured isotype switching to IgG3. After stimulation with LPS or LPS and anti-dextran in culture, AIDS38A B cells showed 19 or 16% the level of CSR to IgG3 of wild-type controls, whereas AIDT140A produced a milder defect resulting in 71 or 52% wild-type CSR (Fig. 3, E and F). We conclude that both AID-S38 and -T140 phosphorylation are required for physiological levels of CSR, but neither is essential for this reaction.
###end p 21
###begin p 22
###xml 10 14 10 14 <sup xmlns:xlink="http://www.w3.org/1999/xlink">S38A</sup>
###xml 22 27 22 27 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T140A</sup>
###xml 0 33 0 33 <bold xmlns:xlink="http://www.w3.org/1999/xlink">CSR in AID<sup>S38A</sup> and AID<sup>T140A</sup> mice.</bold>
###xml 64 67 64 67 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 72 75 72 75 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/&#8722;</sup>
###xml 80 87 80 87 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T140A/&#8722;</sup>
###xml 92 98 92 98 <sup xmlns:xlink="http://www.w3.org/1999/xlink">S38A/&#8722;</sup>
###xml 119 124 119 124 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T140A</sup>
###xml 133 137 133 137 <sup xmlns:xlink="http://www.w3.org/1999/xlink">S38A</sup>
###xml 311 314 311 314 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 319 324 319 324 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T140A</sup>
###xml 333 337 333 337 <sup xmlns:xlink="http://www.w3.org/1999/xlink">S38A</sup>
###xml 350 353 350 353 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/&#8722;</sup>
###xml 358 361 358 361 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 366 373 366 373 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T140A/&#8722;</sup>
###xml 381 387 381 387 <sup xmlns:xlink="http://www.w3.org/1999/xlink">S38A/&#8722;</sup>
###xml 457 458 457 458 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 550 555 550 555 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T140A</sup>
###xml 564 568 564 568 <sup xmlns:xlink="http://www.w3.org/1999/xlink">S38A</sup>
###xml 581 588 581 588 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T140A/&#8722;</sup>
###xml 593 599 593 599 <sup xmlns:xlink="http://www.w3.org/1999/xlink">S38A/&#8722;</sup>
###xml 608 611 608 611 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/&#8722;</sup>
###xml 867 870 866 869 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 879 884 878 883 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T140A</sup>
###xml 893 897 892 896 <sup xmlns:xlink="http://www.w3.org/1999/xlink">S38A</sup>
###xml 1029 1037 1028 1036 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 D</xref>
###xml 1164 1167 1163 1166 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1231 1235 1230 1234 <sup xmlns:xlink="http://www.w3.org/1999/xlink">S38A</sup>
###xml 1272 1277 1271 1276 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T140A</sup>
###xml 1333 1336 1332 1335 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1345 1350 1344 1349 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T140A</sup>
###xml 1359 1363 1358 1362 <sup xmlns:xlink="http://www.w3.org/1999/xlink">S38A</sup>
###xml 1447 1448 1446 1447 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 28 32 <span type="species:ncbi:10090">mice</span>
CSR in AIDS38A and AIDT140A mice. (A) Anti-AID immunoblot of AID-/-, AID+/-, AIDT140A/-, AIDS38A/-, wild-type (WT), AIDT140A, and AIDS38A B cells stimulated with LPS and IL-4. Anti-tubulin immunoblot was used as a loading control. (B) Flow cytometric analysis of IgG1 expression and CFSE dye dilution by WT, AID-/-, AIDT140A, and AIDS38A (top) or AID+/-, AID-/-, AIDT140A/-, or AIDS38A/- B cells (bottom) stimulated with LPS and IL-4. The percentage of IgG1+ cells is indicated on the top right of each graph. (C) Isotype switching to IgG1 by WT, AIDT140A, and AIDS38A (top) or AIDT140A/-, AIDS38A/-, and AID+/- cells (bottom) as in B for the indicated number of independent experiments. Solid lines represent means. Bar graphs represent the mean relative efficiency and SD of IgG1 CSR compared with WT. (D) Number of mutations in the 5' of Smu region cloned from AID-/-, WT, AIDT140A, and AIDS38A B cells stimulated with LPS and IL-4 sorted for IgM expression and five cell divisions. Pie charts and statistical analysis, as in Fig. 2 D, represent summary of two experiments. The numbers of point mutations were as follows: 3 mutations/59,185 bp mutations for AID-/-; 18 mutations/77,875 bp for WT; 11 mutations/115,255 bp for AIDS38A; and 24 mutations/117,747 bp for AIDT140A. (E) Flow cytometric analysis of IgG3 expression in AID-/-, WT, AIDT140A, and AIDS38A B cells stimulated with LPS or LPS and anti-dextran for 6 d. The percentage of IgG3+ cell is indicated on the top left of each graph. (F) Results of E from three independent experiments. Solid line represents the mean.
###end p 22
###begin p 23
###xml 107 108 107 108 <sub xmlns:xlink="http://www.w3.org/1999/xlink">H</sub>
###xml 147 149 147 149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib46">46</xref>
###xml 169 173 169 173 <sup xmlns:xlink="http://www.w3.org/1999/xlink">S38A</sup>
###xml 254 262 254 262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 A</xref>
###xml 281 286 281 286 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T140A</sup>
###xml 429 433 429 433 <sup xmlns:xlink="http://www.w3.org/1999/xlink">S38A</sup>
###xml 435 443 435 443 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 A</xref>
###xml 532 536 532 536 <sup xmlns:xlink="http://www.w3.org/1999/xlink">S38A</sup>
###xml 544 549 544 549 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T140A</sup>
###xml 593 601 593 601 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 B</xref>
###xml 716 719 716 719 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/&#8722;</sup>
###xml 738 746 738 746 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 A</xref>
###xml 812 818 812 818 <sup xmlns:xlink="http://www.w3.org/1999/xlink">S38A/&#8722;</sup>
###xml 826 833 826 833 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T140A/&#8722;</sup>
###xml 921 924 921 924 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 948 956 948 956 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 A</xref>
###xml 1069 1077 1069 1077 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 B</xref>
###xml 1253 1261 1253 1261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 C</xref>
To examine the role of AID phosphorylation in SHM, we cloned and sequenced the DNA region downstream of IgJH4 from purified lymph node GC B cells (46). The effect of AIDS38A on somatic mutation was similar to CSR, resulting in 30% of wild-type activity (Fig. 4 A). In contrast, AIDT140A had more profound effects on somatic mutation than CSR, resulting in 45% of wild-type activity, which was not significantly different from AIDS38A (Fig. 4 A). Similar results were obtained from Peyer's patch B cells, where mutation rates for AIDS38A and AIDT140A were 20 and 40% of controls, respectively (Fig. 4 B). Haploinsufficiency by itself resulted in a mild decrease in hypermutation with 70% hypermutation activity in AID+/- versus wild type (Fig. 4 A). Haploinsufficiency magnified the defect in hypermutation of AIDS38A/- and AIDT140A/-, with neither statistically rising above the background levels of mutation found in AID-/- lymph node GC B cells (Fig. 4 A). Similar, but slightly less pronounced, effects were found in chronically stimulated Peyer's patch GC B cells (Fig. 4 B). We conclude that both AID-S38 and -T140 phosphorylation are required for optimal somatic mutation and that the T140 has a more profound effect on this reaction than on CSR (Fig. 4 C).
###end p 23
###begin p 24
###xml 26 30 26 30 <sup xmlns:xlink="http://www.w3.org/1999/xlink">S38A</sup>
###xml 38 43 38 43 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T140A</sup>
###xml 0 49 0 49 <bold xmlns:xlink="http://www.w3.org/1999/xlink">SHM in GC B cells from AID<sup>S38A</sup> and AID<sup>T140A</sup> mice.</bold>
###xml 118 121 118 121 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 126 129 126 129 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/&#8722;</sup>
###xml 134 141 134 141 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T140A/&#8722;</sup>
###xml 146 152 146 152 <sup xmlns:xlink="http://www.w3.org/1999/xlink">S38A/&#8722;</sup>
###xml 161 166 161 166 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T140A</sup>
###xml 174 178 174 178 <sup xmlns:xlink="http://www.w3.org/1999/xlink">S38A</sup>
###xml 260 261 260 261 <sub xmlns:xlink="http://www.w3.org/1999/xlink">H</sub>
###xml 397 400 397 400 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 465 469 465 469 <sup xmlns:xlink="http://www.w3.org/1999/xlink">S38A</sup>
###xml 505 510 505 510 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T140A</sup>
###xml 557 560 557 560 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 592 595 592 595 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/&#8722;</sup>
###xml 626 632 626 632 <sup xmlns:xlink="http://www.w3.org/1999/xlink">S38A/&#8722;</sup>
###xml 667 674 667 674 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T140A/&#8722;</sup>
###xml 839 842 839 842 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 906 910 906 910 <sup xmlns:xlink="http://www.w3.org/1999/xlink">S38A</sup>
###xml 946 951 946 951 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T140A</sup>
###xml 998 1001 998 1001 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1033 1036 1033 1036 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/&#8722;</sup>
###xml 1067 1073 1067 1073 <sup xmlns:xlink="http://www.w3.org/1999/xlink">S38A/&#8722;</sup>
###xml 1109 1116 1109 1116 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T140A/&#8722;</sup>
###xml 1223 1230 1223 1230 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T140A/&#8722;</sup>
###xml 1235 1241 1235 1241 <sup xmlns:xlink="http://www.w3.org/1999/xlink">S38A/&#8722;</sup>
###xml 1246 1251 1246 1251 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T140A</sup>
###xml 1259 1263 1259 1263 <sup xmlns:xlink="http://www.w3.org/1999/xlink">S38A</sup>
###xml 1267 1270 1267 1270 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/&#8722;</sup>
###xml 1339 1353 1339 1353 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Figs. 3 C, 3 D</xref>
###xml 44 48 <span type="species:ncbi:10090">mice</span>
###xml 179 183 <span type="species:ncbi:10090">mice</span>
SHM in GC B cells from AIDS38A and AIDT140A mice. (A) GC B cells were purified from the lymph nodes of 5 immunized AID-/-, AID+/-, AIDT140A/-, AIDS38A/-, WT, AIDT140A, or AIDS38A mice. Pie charts indicated the number of mutations in the intronic region 3' of JH4. Pie charts and statistical analysis as in 2D. The numbers of point mutations were as follows: 2 mutations/33,666 bp mutations for AID-/-; 184 mutations/115,116 bp for WT; 41 mutations/96,654 bp for AIDS38A; and 65 mutations/85,794 bp for AIDT140A (top). 2 mutations/43,440 bp mutations for AID-/-; 51 mutations/46,689 bp for AID+/-; 5 mutations/66,246 bp for AIDS38A/-; and 8 mutations/71,676 bp for AIDT140A/- (bottom). (B) GC B cells purified from Peyer's patch analyzed the same as A. The numbers of point mutations were as follows: 2 mutations/43,983 bp mutations for AID-/-; 227 mutations/45,612 bp for WT; 33 mutations/35,295 bp for AIDS38A; and 95 mutations/46,698 bp for AIDT140A (top). 1 mutation/179,191 bp mutations for AID-/-; 34 mutations/20,091 bp for AID+/-; 4 mutations/31,494 bp for AIDS38A/-; and 12 mutations/17,919 bp for AIDT140A/- (bottom). (C) Summary of efficiency of both SHM and isotype switching to IgG1 relative to wild-type by AIDT140A/-, AIDS38A/-, AIDT140A,and AIDS38A/AID+/- cells. Bars represent the means from and statistics are reported in Figs. 3 C, 3 D, and 4 [A and B].
###end p 24
###begin p 25
###xml 69 71 69 71 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib12">12</xref>
###xml 73 75 73 75 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib14">14</xref>
###xml 204 207 204 207 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 212 215 212 215 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/&#8722;</sup>
###xml 220 227 220 227 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T140A/&#8722;</sup>
###xml 232 238 232 238 <sup xmlns:xlink="http://www.w3.org/1999/xlink">S38A/&#8722;</sup>
###xml 260 275 260 275 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5, A and B</xref>
###xml 381 384 381 384 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 465 468 465 468 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/&#8722;</sup>
###xml 527 542 527 542 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5, A and B</xref>
###xml 593 599 593 599 <sup xmlns:xlink="http://www.w3.org/1999/xlink">S38A/&#8722;</sup>
###xml 731 734 731 734 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/&#8722;</sup>
###xml 745 760 745 760 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5, A and B</xref>
###xml 14 18 <span type="species:ncbi:10090">mice</span>
###xml 23 29 <span type="species:ncbi:9606">humans</span>
###xml 254 258 <span type="species:ncbi:10090">mice</span>
###xml 385 389 <span type="species:ncbi:10090">mice</span>
###xml 441 445 <span type="species:ncbi:10090">mice</span>
###xml 487 491 <span type="species:ncbi:10090">mice</span>
###xml 600 604 <span type="species:ncbi:10090">mice</span>
###xml 818 822 <span type="species:ncbi:10090">mice</span>
AID-deficient mice and humans have large GCs compared with controls (12, 14). To determine whether this effect is caused by loss of AID protein or its activity, we measured the number of GC B cells in AID-/-, AID+/-, AIDT140A/-, AIDS38A/-, and wild-type mice (Fig. 5, A and B). We found that the amount of AID activity was inversely proportional to the size of the GC response. AID-/- mice showed the highest number of GC B cells, wild-type mice the fewest, and AID+/- haploinsufficient mice were intermediate between the two (Fig. 5, A and B). Decreasing AID activity, but not protein, in AIDS38A/- mice resulted in an increase in the number of GC B cells proportional with the relative decrease in activity when compared with AID+/- controls (Fig. 5, A and B). We conclude that the number of GC B cells in immunized mice is inversely proportional to the amount of AID activity.
###end p 25
###begin p 26
###xml 33 37 33 37 <sup xmlns:xlink="http://www.w3.org/1999/xlink">S38A</sup>
###xml 45 50 45 50 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T140A</sup>
###xml 0 56 0 56 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Percentage of GC B cells from AID<sup>S38A</sup> and AID<sup>T140A</sup> mice.</bold>
###xml 118 119 118 119 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 122 123 122 123 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 141 144 141 144 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 149 152 149 152 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/&#8722;</sup>
###xml 157 164 157 164 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T140A/&#8722;</sup>
###xml 169 175 169 175 <sup xmlns:xlink="http://www.w3.org/1999/xlink">S38A/&#8722;</sup>
###xml 280 283 280 283 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 288 291 288 291 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/&#8722;</sup>
###xml 296 303 296 303 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T140A/&#8722;</sup>
###xml 308 314 308 314 <sup xmlns:xlink="http://www.w3.org/1999/xlink">S38A/&#8722;</sup>
###xml 51 55 <span type="species:ncbi:10090">mice</span>
###xml 196 200 <span type="species:ncbi:10090">mice</span>
###xml 323 327 <span type="species:ncbi:10090">mice</span>
###xml 361 365 <span type="species:ncbi:10090">mice</span>
###xml 430 435 <span type="species:ncbi:10090">mouse</span>
Percentage of GC B cells from AIDS38A and AIDT140A mice. (A) Representative FACS analysis that shows percentage of FAS+GL7+ GC B cells in AID-/-, AID+/-, AIDT140A/-, AIDS38A/-, and wild-type (WT) mice 10 d after immunization. (B) Percentage of GC B cells in the lymph nodes of AID-/-, AID+/-, AIDT140A/-, AIDS38A/-, and WT mice 10 d after immunization from 6-8 mice. Each point represents an immunization experiment from a single mouse.
###end p 26
###begin title 27
DISCUSSION
###end title 27
###begin p 28
###xml 64 66 64 66 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib12">12</xref>
###xml 68 70 68 70 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib14">14</xref>
###xml 180 186 180 186 <sup xmlns:xlink="http://www.w3.org/1999/xlink">S38A/&#8722;</sup>
###xml 590 591 590 591 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib3">3</xref>
###xml 593 594 593 594 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib4">4</xref>
###xml 707 709 707 709 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib47">47</xref>
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
###xml 9 15 <span type="species:ncbi:9606">humans</span>
###xml 135 139 <span type="species:ncbi:10090">mice</span>
###xml 187 191 <span type="species:ncbi:10090">mice</span>
Mice and humans deficient in AID have larger GCs than controls (12, 14). In this study, we observe larger GCs in AID-haploinsufficient mice together with further enlargement in AIDS38A/- mice, indicating that the GC phenotype is directly related to the level of AID activity. AID activity might impact GC size by a variety of mechanisms, including antibody gene or generalized genomic damage. For example, increased AID activity could result in higher rates of detrimental antibody gene mutation, leading to loss of affinity, loss of expression, or development of self-reactive antibodies (3, 4). Conversely, higher rates of off-target genomic damage by AID may lead to mutations that result in cell death (47). Irrespective of the mechanism, the magnitude of the effect of AID levels on GC size emphasizes the importance of AID regulation in vivo.
###end p 28
###begin p 29
###xml 174 176 174 176 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib37">37</xref>
###xml 313 315 313 315 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib48">48</xref>
###xml 455 457 455 457 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib37">37</xref>
###xml 1001 1003 1001 1003 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib49">49</xref>
###xml 1005 1007 1005 1007 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib50">50</xref>
###xml 1026 1030 1026 1030 <sup xmlns:xlink="http://www.w3.org/1999/xlink">S38A</sup>
###xml 1390 1392 1390 1392 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib29">29</xref>
Phosphorylation of AID at position S38 is believed to facilitate the interaction between AID and RPA, a cofactor that is required for AID to access transcribed DNA in vitro (37). RPA binds to ssDNA and it was proposed that RPA might stabilize ssDNA liberated during transcription to serve as a substrate for AID (48). Consistent with this idea, AID-S38A is inactive on transcribed dsDNA in the absence of RPA, while retaining catalytic activity on ssDNA (37). Nevertheless, AID-S38A is active at between 20 and 35% of wild-type levels in hypermutation and CSR in vivo. One way to reconcile these results would be to posit that association between AID and RPA is only required for a subset of AID substrates that do not stabilize ss regions spontaneously. For example, ssDNA in switch regions is stabilized spontaneously by R-loops, but this does not occur in Ig variable region DNA. This model might predict that the S38A mutation would preferentially interfere with Ig variable region hypermutation (49, 50). However, the AIDS38A mutation affects switching and mutation equally; therefore, the mechanism by which S38 phosphorylation alters AID function is likely to be independent of whether the ssDNA substrate is created by R-loops. An alternative nonexclusive explanation for our results is that S38 phosphorylation enhances AID activity by facilitating its interaction with chromatin (29).
###end p 29
###begin p 30
###xml 262 264 262 264 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ig</italic>
###xml 280 282 280 282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib39">39</xref>
###xml 544 546 544 546 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib29">29</xref>
Biochemical studies with AID purified from insect cells assayed on artificial substrates showed that S38A mutation does not alter overall AID activity, but shifts target preference in a way that might result in specific loss of activity on hotspots found in the Ig switch region (39). This in vitro bias is not consistent with our mutation data in transfected fibroblasts or GC B cells because we find lower levels of SHM in all cases and the selective hotspot bias found in the in vitro transcription systems would not affect the rate of SHM (29).
###end p 30
###begin p 31
###xml 252 254 252 254 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib37">37</xref>
###xml 256 258 256 258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib38">38</xref>
###xml 388 396 388 396 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 E</xref>
###xml 498 506 498 506 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 F</xref>
###xml 557 565 557 565 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 B</xref>
###xml 803 805 803 805 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib51">51</xref>
###xml 807 809 807 809 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib52">52</xref>
###xml 958 960 958 960 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib51">51</xref>
Previous coimmunoprecipitation and in vitro kinase experiments suggest that PKA phosphorylates AID at S38; the importance of this kinase in regulating AID is supported by the finding that inhibition of its activity in B cells inhibits class switching (37, 38). Our experiments indicate that T140 is not a PKA target site, and that S38 can be phosphorylated by either PKA or PKC in vitro (Fig. 1 E). In addition, PKC family members overlap in their preference to phosphorylate T140 or S38 in vitro (Fig. 1 F) and S38 or T140 phosphorylation is nonexclusive (Fig. 2 B). Thus, AID activity may be modulated by phosphorylation on one or both sites, depending on which kinase is activated. The PKC family is composed of at least 10 serine/threonine kinases, many of which are expressed in activated B cells (51, 52). They have been implicated in a wide variety of cellular processes, including growth, differentiation, tolerance, immunity, and tumor development (51). Which family members phosphorylate AID and the precise pathways that regulate phosphorylation in vivo remains to be determined.
###end p 31
###begin p 32
###xml 409 411 409 411 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ig</italic>
###xml 802 804 801 803 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ig</italic>
###xml 869 877 868 876 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 C</xref>
###xml 1210 1212 1209 1211 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib45">45</xref>
###xml 1214 1216 1213 1215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib53">53</xref>
How T140 phosphorylation modulates AID activity is not known, but this modification differs from S38 in that it preferentially affects somatic mutation. Differential regulation of class switching and somatic mutation is a well-characterized physiological feature of gene diversification in B cells. For example, B cells undergoing switch recombination in response to LPS and IL-4 in vitro do not mutate their Ig variable regions. This cannot be ascribed to a general absence of the factors that mediate hypermutation because the DNA 3' of the Imu promoter and the switch regions themselves are mutated by AID in LPS- and IL-4-stimulated B cells. Indeed, the amount of mutation in switch regions in AID-T140A-expressing B cells is directly proportional to the amount of class switching and differs from Ig variable region gene mutation, which is more severely affected (Fig. 4 C). One explanation for the disparity between the effects of AID-T140A on switching and mutation would be that there are specific requirements for AID in the two reactions. This idea is supported by the finding that mutations in the amino or carboxyl terminal regions of AID preferentially affect somatic mutation or class switching (45, 53). Finding that phosphorylation at T140 preferentially affects somatic mutation suggests a mechanism by which AID activity on closely related substrates might be differentially regulated.
###end p 32
###begin p 33
###xml 400 408 400 408 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 C</xref>
###xml 449 452 449 452 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/&#8722;</sup>
###xml 513 519 513 519 <sup xmlns:xlink="http://www.w3.org/1999/xlink">S38A/&#8722;</sup>
###xml 526 534 526 534 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 C</xref>
###xml 551 558 551 558 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T140A/&#8722;</sup>
###xml 637 640 637 640 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/&#8722;</sup>
###xml 666 674 666 674 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 C</xref>
###xml 793 796 793 796 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/&#8722;</sup>
###xml 804 811 804 811 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T140A/&#8722;</sup>
###xml 841 846 841 846 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T140A</sup>
###xml 866 881 866 881 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4, A and B</xref>
###xml 1181 1183 1181 1183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib25">25</xref>
###xml 520 524 <span type="species:ncbi:10090">mice</span>
AID activity is regulated by several mechanisms, including restricted expression, mRNA stability, nuclear degradation, nuclear export, and multiple phosphorylation sites. Although each of these alone appears to have a small effect on CSR and SHM, the combined effects are dramatic. For example AID haploinsufficiency supports rates of 80 and 70% of wild type in CSR and lymph node SHM, respectively (Fig. 4 C). However, CSR is decreased to 5% of AID+/- controls, and lymph node SHM was at background levels in AIDS38A/- mice (Fig. 4 C). Similarly, AIDT140A/- B cells were severely, but selectively, impaired in lymph node SHM (10% of AID+/- vs. 57% for CSR to IgG1; Fig. 4 C). Peyer's patch B cells supported SHM levels nearly three times higher then lymph node. In this case, SHM rates in AID+/- and AIDT140A/- resemble those of AID and AIDT140A in the lymph node (Fig. 4, A and B). Thus, AID appears to be controlled by multiple potentially overlapping mechanisms. We speculate that this type of combinatorial regulation facilitates fine control of AID levels, which is required because small imbalances in its expression can result in catastrophic effects on genomic stability (25).
###end p 33
###begin title 34
MATERIALS AND METHODS
###end title 34
###begin title 35
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice.
###end title 35
###begin p 36
###xml 14 18 14 18 <sup xmlns:xlink="http://www.w3.org/1999/xlink">S38A</sup>
###xml 26 31 26 31 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T140A</sup>
###xml 727 730 727 730 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 745 747 745 747 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib12">12</xref>
###xml 763 766 763 766 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/&#8722;</sup>
###xml 771 777 771 777 <sup xmlns:xlink="http://www.w3.org/1999/xlink">S38A/&#8722;</sup>
###xml 785 792 785 792 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T140A/&#8722;</sup>
###xml 32 36 <span type="species:ncbi:10090">mice</span>
###xml 703 707 <span type="species:ncbi:10090">Mice</span>
###xml 739 743 <span type="species:ncbi:10090">mice</span>
###xml 793 797 <span type="species:ncbi:10090">mice</span>
###xml 915 919 <span type="species:ncbi:10090">mice</span>
To produce AIDS38A and AIDT140A mice, AID S38 or T140 was mutated to alanine using the same gene-targeting strategy (Fig. S1). The long arm of the targeting vector was 5 kb long with 3' within the intron between AID exons 2 and 3 (Fig. S1). The short arm was a 3.3-kb fragment extending with the 3' into the intron between exons 3 and 4. A LoxP-flanked neomycin-resistance gene was used for positive selection, and a diphtheria toxin gene was used for negative selection. The targeting construct was linearized and transfected into C57BL/6 embryonic stem cells. The genotype was confirmed by Southern blot and PCR amplification using a primer outside of the targeting construct, followed by sequencing. Mice were crossed to AID-/- C57BL/6 mice (12) to produce AID+/-, AIDS38A/-, or AIDT140A/- mice used for analysis. The presence of mutants were confirmed by RT-PCR and sequencing of AID mRNA. All experiments with mice were done according to protocols approved by the Rockefeller University Institutional Animal Care and Use Committee.
###end p 36
###begin title 37
Lymphocyte isolation and culturing and retroviral infection.
###end title 37
###begin p 38
###xml 94 96 94 96 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib29">29</xref>
###xml 244 249 <span type="species:ncbi:10090">mouse</span>
###xml 561 566 <span type="species:ncbi:10090">mouse</span>
Lymphocyte isolation, cultures, retrovirus infection, and analysis were previously described (29). The PMX-MK-AID was the same as the previously described PMX-AID, except the Kozak CCACCATGG was changed to GGTTTATGG. B cells were purified from mouse spleens by depletion with anti-CD43 beads (Miltenyi Biotec) and cultured in 25 mug/ml LPS (Sigma-Aldrich) alone for switching to IgG3 or with 5 ng/ml IL-4 (Sigma-Aldrich) for IgG1or with 2.5 ng/ml anti-alpha-delta-dextran (Fina BioSolutions) for IgG3. Cells were stained with CSFE and/or with biotinylated anti-mouse IgG1 or IgG3 antibodies and streptavidin APC (BD Biosciences).
###end p 38
###begin title 39
PCR and mutation analysis.
###end title 39
###begin p 40
###xml 731 732 730 731 <sub xmlns:xlink="http://www.w3.org/1999/xlink">H</sub>
###xml 1124 1125 1086 1087 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1258 1260 1220 1222 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib29">29</xref>
###xml 1386 1388 1348 1350 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib33">33</xref>
###xml 1390 1392 1352 1354 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib44">44</xref>
###xml 1488 1495 1450 1457 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli</italic>
###xml 1551 1553 1513 1515 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib19">19</xref>
###xml 42 46 <span type="species:ncbi:10090">mice</span>
###xml 436 440 <span type="species:ncbi:10090">mice</span>
###xml 1141 1145 <span type="species:ncbi:10090">mice</span>
###xml 1488 1495 <span type="species:ncbi:562">E. coli</span>
For SHM analysis, age-matched 8-16-wk-old mice were immunized by footpad injected with 50 mug of NP-CGG (Biosearch Technologies) precipitated in alum and lymph node, and Peyer's patches were dissected 11 d after immunization. GC B cells were stained with APC anti-CD19, FITC anti-GL7, and PE anti-FAS antibodies (BD Biosciences) and purified by cell sorting. In two independent experiments, DNA samples were pooled from 2 or 3 separate mice. To amplify the intronic region 3' of JH4, four separate PCR reactions were performed on each sample with PFU polymerase (Stratagene) on genomic DNA from 5,000 equivalent cells. Amplified products were pooled, cloned, and sequenced. The intron region 3' of JH4 was amplified with a common VHJ558 family primer (5'-GGAATTCGCCTGACATCTGAGGACTCTGC-3') and (5'-CTGGACTTTCGGTTTGGTG-3') for 9 cycles at 94degreesC (30 s), at 55degreesC (30 s), and at 72degreesC (90 s), and then (5'-GGTCAAGGAACCTCAGTCA-3') and (5'-TCTCTAGACAGCAACTAC-3') for 21 cycles at 94degreesC (30 s), at 55degreesC (30 s), and at 72degreesC (30 s). For 5'mu switch region analysis after 96-h LPS/IL-4 stimulation, IgM+ cells from two mice that CFSE labeling indicated had divided 5 times were sorted. Conditions and primers were previously described (29). The NTZ-3T3 assay and GFP gene mutational analysis were performed as previously described 11 d after retrovirus infection (33, 44). PCR products were cloned into TOPO-TA cloning kit (Invitrogen) and sequenced with T7 primer. E. coli assays were performed exactly as previously described (19).
###end p 40
###begin title 41
Protein analysis.
###end title 41
###begin p 42
###xml 56 58 56 58 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib29">29</xref>
###xml 1295 1296 1293 1294 <sup xmlns:xlink="http://www.w3.org/1999/xlink">9</sup>
###xml 1507 1509 1504 1506 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib29">29</xref>
###xml 94 101 <span type="species:ncbi:9986">rabbits</span>
###xml 1329 1334 <span type="species:ncbi:10090">mouse</span>
Anti-AID and -p38 antibodies were previously described (29). To produce anti-p140 antibodies, rabbits were immunized with phosphopeptide GVQIGIM(pT)FKDYFYC (AID 133-148) coupled to keyhole limpet hemocyanin. Phosphospecific antibodies were purified by negative selection on unphosphorylated peptide AID 133-148 coupled to Sulfolink gel (Thermo Fisher Scientific), followed by positive selection on the phosphopeptide. Cells were extracted in lysis buffer (20 mM Tris, pH 8.0, 400 mM NaCl, 1% Nonidet P-40, 0.5 mM EDTA, 25 mM NaF, and 1 mM DTT). For immunoprecipitation, 2 mg of extracts were incubated with anti-AID antibody and protein A-Sepharose (GE Healthcare) for 2 h. For FLAG immunoprecipitation, anti-FLAG agarose beads (Sigma-Aldrich) were incubated with extracts for 2 h and AID was eluted with 0.5 mug/ml of FLAG peptide (Sigma-Aldrich) in lysis buffer. Western blots were performed on immunoprecipitated protein or on 50 mug of total cell extracts with the indicated anti-AID antibody; anti-tubulin (Abcam) was used as a loading control. To compare AID levels from retroviral-infected B cells, Western blots were performed on cells sorted for GFP expression. AID purification and mass spectrometry analysis of phosphorylation was performed as previously described on extracts from 109 wild-type B cells purified from mouse spleens by depletion with anti-CD43 beads (Miltenyi Biotec) and cultured in RPMI medium, 10% FBS, 5 ng/ml IL-4 (Sigma-Aldrich), and 25 mug/ml LPS (Sigma-Aldrich) for 72 h (29).
###end p 42
###begin title 43
In vitro phosphorylation.
###end title 43
###begin p 44
###xml 91 93 91 93 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib29">29</xref>
###xml 242 243 236 237 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
100 ng of purified recombinant AID protein was incubated with PKA as previously described (29) or 0.1 U of PKC catalytic subunit or isoforms (Calbiochem) for 30 min at 30degreesC in a buffer containing 40 mM MES, pH 6.0, 1 mM EGTA, 10 mM MgCl2, 1 mM DTT, and 0.1 mM ATP.
###end p 44
###begin title 45
Online supplemental material.
###end title 45
###begin p 46
###xml 52 56 52 56 <sup xmlns:xlink="http://www.w3.org/1999/xlink">S38A</sup>
###xml 64 69 64 69 <sup xmlns:xlink="http://www.w3.org/1999/xlink">T140A</sup>
###xml 70 74 <span type="species:ncbi:10090">mice</span>
Fig. S1 shows gene-targeting strategy to produce AIDS38A and AIDT140A mice. The online supplemental material is available at .
###end p 46
###begin title 47
Supplementary Material
###end title 47
###begin title 48
[Supplemental Material Index]
###end title 48
###begin p 49
###xml 121 125 <span type="species:ncbi:10090">mice</span>
We thank the members of the Nussenzweig laboratory, K. Velizon, and T. Shengelia for cell sorting, and T. Eisenreich for mice breeding.
###end p 49
###begin p 50
This work was supported in part by National Institutes of Health grants (to B.T. Chait and M.C. Nussenzweig). M.C. Nussenzweig is a Howard Hughes Medical Institute Investigator.
###end p 50
###begin p 51
The authors have no conflicting financial interests.
###end p 51

